Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 890.04M P/E - EPS this Y 32.00% Ern Qtrly Grth -
Income -67.06M Forward P/E -27.19 EPS next Y -13.00% 50D Avg Chg -2.00%
Sales 4.09M PEG -0.94 EPS past 5Y - 200D Avg Chg 91.00%
Dividend N/A Price/Book 4.44 EPS next 5Y 21.70% 52W High Chg -13.00%
Recommedations 2.60 Quick Ratio 12.46 Shares Outstanding 63.29M 52W Low Chg 3,763.00%
Insider Own 2.10% ROA -18.62% Shares Float 21.92M Beta -
Inst Own 103.43% ROE -37.23% Shares Shorted/Prior 1.16M/1.74M Price 14.68
Gross Margin 100.00% Profit Margin - Avg. Volume 419,328 Target Price 28.67
Oper. Margin -48,350.94% Earnings Date - Volume 499,565 Change -2.52%
About Ambrx Biopharma Inc.

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. As of March 7, 2024, Ambrx Biopharma Inc. operates as a subsidiary of Johnson & Johnson.

Ambrx Biopharma Inc. News
03/06/24 Ambrx Shareholders Approve Acquisition by Johnson & Johnson
01/08/24 Ambrx Announces Sale to Johnson & Johnson
12/14/23 Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
11/28/23 Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
10/23/23 Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments
10/16/23 Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress
09/26/23 Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
09/18/23 Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
09/05/23 Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences
08/11/23 RBC Predicts 100% Gains for These 2 Stocks — Here’s Why They Have Strong Upside
08/01/23 Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs
07/28/23 Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023
08:03 AM FDA Grants Fast Track Designation for Ambrx’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
07/02/23 TipRanks ‘Perfect 10’ List: These 2 Top-Rated Stocks Tick All the Boxes
06/28/23 Ambrx Announces Closing of $75 Million Market Priced Registered Offering
06/05/23 Ambrx Appoints Jared Kelly as General Counsel
05/30/23 Ambrx to Present at Multiple Upcoming Investor Meetings
05/24/23 Ambrx Announces $75 Million Market Priced Registered Offering
AMAM Chatroom

User Image Fingerlickengood Posted - 7 hours ago

@Bionco maybe J&J approached ADAP looking at making a potential bid…look what J&J did to $AMAM https://investorplace.com/2024/01/why-is-ambrx-biopharma-amam-stock-up-100-today/

User Image LefDeppard Posted - 19 hours ago

$JAGX I don’t know. Seems like a big ol’ fashioned bear trap. When $AMAM ran from .38 to $28 it experienced plenty of volatile drops. Didn’t stop it in the end. Just sayin’.

User Image LefDeppard Posted - 2 days ago

@Wdino73 could not agree more. $AMAM went from .38 to 28 dollars in two years. It was a grind until the JnJ buyout. This looks amazingly similar. At least up to now.

User Image Earth4thewin Posted - 3 days ago

@Firehorse67 You don't believe $ZVSA can reach that far ? You did see when $AMAM went from 40 cents to 28 Dollars? Supposedly they are sister companies 🤔

User Image LefDeppard Posted - 1 week ago

@TheBrassKing two years. I anticipate an $AMAM type move. $.38 to $28 in two years before JnJ buyout. Maybe it’ll happen maybe it won’t, but looking at the charts, the way it bounced off a nickel is eerily similar to the way #AMAM bouned off its low of .38, just sayin’. Question is, who’s gonna win the buyout when it comes around??

User Image Factanonverba Posted - 1 week ago

$AVXL For those who don't believe in big increases $AMAM was at 0,4$ in 2022. It rose 1000% on December 9th 22. Phase 2 study. Under the rader company, complex and novel technology - sounds familiar? Taken over by J&J in March this year for 28$ per share. Stay long and strong. 24-25 will be very interesting years for us.

User Image DharlMorey2 Posted - 1 week ago

$ATOS Good thing we got the MBD phase-2 results coming -- Atossa new 4 year high coming! 10+ easy $XBI $VKTX $AMAM $GLYC

User Image Earth4thewin Posted - 1 week ago

$ZVSA for the love of God please do like your sister company $AMAM and get bought out by $JNJ 🙏

User Image DharlMorey2 Posted - 04/30/24

$SLS Some large buys/covers coming in today -- would be nice to close this back up over 1.30 at the least. It sounds like we'll have phase-3 data readout in June at the latest. Considering IDMC gave a positive recommendation[1], an no safety issues -- things are looking Stellar for Sellas :) [0] https://ir.sellaslifesciences.com/overview/default.aspx [1] https://ir.sellaslifesciences.com/news/News-Details/2024/SELLAS-Life-Sciences-Announces-Positive-Recommendation-of-Independent-Data-Monitoring-Committee-Following-Completion-of-Enrollment-in-REGAL-Phase-3-Study/default.aspx $XBI $LLY $SYRS $AMAM

User Image Earth4thewin Posted - 04/29/24

@John_D_Stockefeller @LBTheEmcee @canievas can you imagine if we get bought out like $AMAM ? I remember when that ticker went from .48 cents to $28 ,what a ride that was 🥳

User Image John_D_Stockefeller Posted - 04/29/24

@VMAESA @LBTheEmcee Vanessa, I am a loooong term hold, first buy almost a year ago, hoping for a BO, as with their 'sister company of sorts', $AMAM paid off VERY handsomely for me. You're one dumpost away from a Block.

User Image John_D_Stockefeller Posted - 04/29/24

@PolyDirect I first bought almost a year ago. Been adding, up to the r/s. I've got nothing but time to see if this goes the way of $AMAM. Not saying I think much of anything you post, but find it odd that you're here, and haven't been recruited to the Harvard campus, where your talents could be better used.

User Image John_D_Stockefeller Posted - 04/29/24

@BusyMind I made SERIOUS bank on $AMAM, after holding/adding for an extended period, and took a good-sized position here, starting almost a year ago. Also, been adding, especially after the #AMAM buyout. Prepared to hold for yeeears if need be. zzzzz

User Image John_D_Stockefeller Posted - 04/23/24

$ZVSA Glover must be really inept…..bought in here hoping for a play out like $AMAM. Glover might just be content with a nice view from his office, golf on company time, 5-Michelson lunches, and a never-ending, big paycheck. IMO.

User Image AndersKingern_ Posted - 1 month ago

$SLS squeeze potential with data coming next week $TPST $AMAM

User Image Ozibozi Posted - 1 month ago

$ALT check $amam chart…

User Image DaBullRunner Posted - 1 month ago

Thought I was finished????? I have enough highlight reels to last years folks Stay with me on this one….. Although I didn’t state it I did have an inkling that $AMAM would be bought out around the $12’s You may think I’m making this up but IDGAF what you think I’m telling you these Parkinson’s/ Alzheimer’s tickers could change your entire account around And like I said, $ATHE is not in Phase 1 folks They actually produced positive Phase 2 results 🚨LET THAT SINK IN🚨 The current market cap doesn’t this imo

User Image CHCInvestments Posted - 1 month ago

$PHAT Any of you guys or gals been in this stock a while and follow it closely? I am just looking for input from people who plan to hold this long term. I had a large position in $AMAM and sold it a short time ago.....and have been sitting on that cash. I would like to put it to work and have been watching this closely. I missed entering last week in mid $9's...but thinking about starting to add this dip and just averaging down if it drops and writing covered calls. Looks like mid $7's would be the very lowest, but mid 9's more likely to get bought up again. I have a bunch of questions....but how about some of you tell me the pros and cons of this company. Looks like around 60M float, good bit of cash, expected revenue, high short %. What kind of revenue they expect in next year or so? Any chance a bigger company buys this out, like happened to AMAM? I appreciate your folks input. Thanks!!

User Image DharlMorey2 Posted - 1 month ago

$ATOS Insider buys at Atossa -- big moves coming. - $SLS looks like it wants to gamma squeeze with the call buying, lack of sellers, and nearly 100% cost-to-borrow for shorts. - $CADL - Probably a buyout candidate, not sure on timeline but reminds me a lot of $AMAM getting scoped up. Bio sector is hot! $XBI

User Image Ridiculous78 Posted - 1 month ago

$ALPN Price action is always telling to a buyout.. Writing was on the wall over at $AMAM and $IMGN as well! $JANX could be next 🤔

User Image DharlMorey2 Posted - 1 month ago

$ATOS Saw the same thing on my $SYRS where it took 2 days for tutes to process the news before a 300% gain. The BIG news: "Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen" ASCO participation is only 14 days away (11 trading days) -- so we're going to know very quickly how big the next round of fireworks are :) May 24th we get the text -- and then a week later Russell 2000/3000 preliminary lists are released -- we may see some serious volume. The news source: https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-presents-data-40mg-cohort-phase-2-evangeline $XBI $AMAM

User Image DharlMorey2 Posted - 1 month ago

$ATOS Double digits by end of year -- buy and hold “The 40mg EVANGELINE data is extremely encouraging as it shows that (Z)-endoxifen can not only stop ER+ breast cancer from growing, but it can also shrink or eliminate the tumor, as measured by MRI imaging,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “The depth of response at 40mg may even improve in the next phase of the study where we are now treating women with 80mg of (Z)-endoxifen daily. We expect this dose to deliver the optimal steady-state plasma concentrations required to fully target PKCβ1 inhibition and further enhance (Z)-endoxifen’s antitumor efficacy.” $JNJ $PFE $AZN $AMAM

User Image Earth4thewin Posted - 1 month ago

This man ,Daniel J. O'Connor CEO of AMBRX $AMAM really will be remembered as a successful individual that obviously knows how to run a company . We need more CEOs like this . 👍 W

User Image DharlMorey2 Posted - 1 month ago

$ATOS So many of you got your shares stolen today -- stop losses off for the last time LOL. Ran it down to 1.60 and bounced back up to 2.04 at one point. Buy. Hold. That's it. Read the post and links below if you need some weekend reading on the company. PR coming next week otherwise to help you understand the data. $XBI $VKTX $AMAM $OCEA

User Image DharlMorey2 Posted - 1 month ago

$ATOS We've known most of the results previously (non-toxicity), but now we know anti-tumor activity has been confirmed. 80mg data going to prove us right :) 80mg cohort completion shortly -- run to 3+ soon. All the shorts loading in now going to get burned :) Hope you didn't lose your stop loss https://www.abstractsonline.com/pp8/#!/20272/presentation/11540 $XBI $AMAM $VKTX

User Image Okenrav Posted - 1 month ago

$AMAM $ATOS $BKNG $VKTX $XBI ATOS is going back to ZERO!

User Image DharlMorey2 Posted - 1 month ago

$ATOS "ENDX (40 mg/day) exhibits promising antitumor activity " -- that's all weI needed to hear. $XBI $BKNG $AMAM $VKTX

User Image DharlMorey2 Posted - 1 month ago

$ATOS (Share everywhere!) https://www.abstractsonline.com/pp8/#!/20272/presentation/11540 "Conclusions: ENDX (40 mg/day) exhibits promising antitumor activity for PM ER+/HER2- BC but with ENDX Css below target. Enrollment is ongoing to the 80 mg/day dose level." $XBI $VKTX $AMAM $BKNG

User Image DharlMorey2 Posted - 1 month ago

$AZN $XBI $ATOS $VKTX $AMAM (Actual PR probably coming out Tuesday/Wednesday though after presentation of data)

User Image DharlMorey2 Posted - 1 month ago

$ATOS 6 minutes: https://www.abstractsonline.com/pp8/#!/20272/presentation/11540 $XBI $AZN $AMAM $VKTX

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Nelson Sonja Chief Financial Offi.. Chief Financial Officer Oct 27 Sell 9.82 12,778 125,480 130,079 10/31/23
O'Connor Daniel J. President and CEO President and CEO Oct 27 Sell 9.82 50,012 491,118 342,845 10/31/23
Cormorant Asset Management, LP 10% Owner 10% Owner Oct 23 Buy 6.9911 1,307,311 9,139,542 11,231,000 10/25/23
Cormorant Asset Management, LP 10% Owner 10% Owner Sep 15 Buy 9.15 2,152,738 19,697,553 69,465,823 09/19/23
Cormorant Asset Management, LP 10% Owner 10% Owner Apr 18 Buy 11.34 5,215,189 59,140,243 67,313,085 04/20/23
Cormorant Asset Management, LP 10% Owner 10% Owner Apr 13 Buy 9.93 2,597,896 25,797,107 62,097,896 04/17/23